US OptionsDetailed Quotes

HCA250516P330000

Watchlist

0.59
-0.76-56.30%

15min DelayClose May 12 16:00 ET

0.59High0.59Low

HCA Healthcare Stock Discussion

Tao Lao Man Official

May 7 04:32

$HCA Healthcare (HCA.US)$
PRO INVESTORS - DJI PULL BACK OR DUMP MORE AND MORE NEXT FEW DAYS, SELL IN MAY FLEE AWAY BECAUSE OWE TOO MUCH 🤔

CCS94

Apr 25 20:25

A great defensive company, HCA Healthcare. It reported better than expected Q1 2025 result

HCA Healthcare $HCA Healthcare (HCA.US)$ beat both Q1 2025 EPS and revenue."The solid fundamentals we saw in our business the past several quarters continued into the first quarter of 2025" - by Sam Hazen, Chief Executive Officer of HCA HealthcareHCA is up about 1.4% pre-market. And based on the technical analysis, if price could break above the 200MA (red line), I foresee it would continue to create a high...

Teddy123

Apr 11 15:43

Two Large Clinical Trials Find a Highly Effective Method to Select Appropriate Antibiotics for Patients Hospitalized With Abdominal or Skin and Soft Tissue Infection

$HCA Healthcare (HCA.US)$
Major Breakthrough: New System Cuts Wrong Antibiotic Use by 35% in Hospital Trials

HotHotHot

Feb 7 03:32

$HCA Healthcare (HCA.US)$ why suddenly go down

韭菜变主力

Jan 2 13:28

$HCA Healthcare (HCA.US)$ It’s buyable in the long term as an investment. Short term might need some time to bottom and there might be some earning deceleration/normalization risk. The chart would touch the up trend started from the pendamic low for the fourth time, which typically means the trend is old.

韭菜变主力

Jan 2 13:12

$HCA Healthcare (HCA.US)$ From 2019 to 2024, the revenue increased by 38%, EPS increased by 108%, that’s a revenue CGAR of 6.6% and EPS CGAR of 15.8%. The EBITDA margin is about the same at 18% in 2019 and 2024. The magic of this outsized EPS growth is share repurchase at a relatively low TTM P/E=13-14. The share price from this period precisely reflected that amazing EPS growth and the P/E didn’t expand. It’s a pretty good investment if the revenue CGAR of 6-7% can be achieved consistently (2-3%...

Tynkr Lab

Oct 26, 2024 11:16

Tech Resilience Boosts NASDAQ as Dow and S&P Edge Lower

Click Here: TYNKR LAB™
The U.S. stock market has shown mixed performance in recent sessions, driven by sector-specific gains and losses. As of the latest close, $Dow Jones Industrial Average (.DJI.US)$ experienced a decline of 0.61%, while $S&P 500 Index (.SPX.US)$ slightly edged down by 0.03%. In contrast, $Nasdaq Composite Index (.IXIC.US)$ saw a modest increase of 0.56%, underscoring the continuing resilience of technology stocks even as oth...

Moomoo News Global

Sep 19, 2024 20:24

Columns Will Rate Cuts Boost the Stock Market? A Global Equity Investment Guide

The Federal Reserve on Wednesday implemented its first rate cut in over four years, reducing the benchmark rate by 50 basis points to a range of 4.75%-5%.
The move surpassed Wall Street's expectations. Analysts had generally anticipated a 25 basis point cut, while the futures market had priced in a 61% probability of a 50 basis point cut and a 39% probability of a 25 basis point reduction.
Market Response to First Rate Cut
St...

Another 25bp Rate Cut! What's next for the market?

Analysts Notebook

Sep 5, 2024 19:06

Columns 'Trump Trade' vs. 'Harris Trade': How They Could Shape Your Portfolio

The 2024 U.S. presidential race between former President Donald Trump and current Vice President Kamala Harris is still "incredibly close," according to the latest New York Times survey. As investors await the outcome of the November election, equity analysts are busy parsing through the candidates' pronouncements for clues on which stocks could benefit from their policies.
Jefferies analysts cited 10 possible policies that Tr...

Trump trade: Bitcoin hit record highs and Tesla hits $1 trillion market cap

Analysts Notebook

Aug 27, 2024 19:33

Columns Ready for Fed Rate Cuts? Biotech's Potential to Watch

The Federal Reserve appears poised to cut interest rates later this year. While the broader stock market might breathe a sigh of relief, certain sectors could be more significantly impacted than others. Biotechnology could be one of those sectors - at least, that's what Morgan Stanley believes.
In 2024, biotech stocks had a slow start, with the S&P Biotechnology Select Industry Index returning just under 4% in the first six months, compared to...

Another 25bp Rate Cut! What's next for the market?

No comment yet